A nutrient/toxin interaction theory of the etiology and pathogenesis of Chronic Pain-Fatigue Syndromes: Part I

Journal of Chronic Fatigue Syndrome

Volumn 5, Issue 1, 1999, Pages 67-91

  Laylander, Julia A ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Chronic fatigue syndrome; Etiology; Fibromyalgia syndrome; Fluoride; Magnesium; Persian Gulf syndrome

Indexed keywords

FLUORIDE; MAGNESIUM;

ARTICLE; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CLINICAL FEATURE; DISEASE COURSE; FIBROMYALGIA; HUMAN; IMMUNOREGULATION; MAGNESIUM DEFICIENCY; MAGNESIUM METABOLISM; NEUROMODULATION; PATHOPHYSIOLOGY; PERSIAN GULF SYNDROME;

EID: 0033056083     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v05n01_07     Document Type: Article

References (98)

1. Knight AL. Fluorides. In: Zenz C, Dickerson OB, Horvath EP, eds. Occupational Medicine. 3rd ed. St. Louis: Mosby; 1994:496-500.
2. Howe-Grant M, ed. Fluorine Chemistry: A Comprehensive Treatment. New York: John Wiley & Sons; 1995.
3. Underwood EJ. Trace Elements in Human and Animal Nutrition. New York: Academic Press; 1971.
4. Navia JM, Aponte-Merced L, Punyasingh K. Fluoride Metabolism in Humans. In: Prasad AS, ed. Essential and Toxic Trace Elements in Human Health and Disease. New York: Alan R. Liss, Inc.; 1988:229-250.
5. Goyer RA. Toxic and Essential Metal Interactions. Annu Rev Nutr. 1997; 17:37-50.
6. Emsley J, Jones DJ, Miller JM, et al. An Unexpectedly Strong Hydrogen Bond: Ab Initio Calculations and Spectroscopic Studies of Amide-Fluoride Systems. J Am Chem Soc. 1981;103:24-28.
7. Messer HH. Fluorine. In: Frieden E, ed. Biochemistry of the Essential Ultratrace Elements. New York: Plenum Press;1984:55-87.
8. Waldbott GL. Fluoride in Clinical Medicine, Int Arch Allergy Appl Immunol. 1962;20(suppl 1):1-60.
9. Galland L. Magnesium, Stress and Neuropsychiatric Disorders. Magnes Trace Elem. 1991-92;10(2-4):287-301.
10. Galland L. Normocalcemic Tetany and Candidiasis. Magnesium. 1985;4: 339-344.
11. Durlach J, Bac P, Durlach V, et al. Neurotic, Neuromuscular and Autonomic Nervous Form of Magnesium Imbalance. Magnes Res. June 1997;10(2):169-195.
12. Cox IM, Campbell MJ, Dowson D. Red Blood Cell Magnesium and Chronic Fatigue Syndrome. Lancet. 1991;337:757-760.
13. Abraham GE, Flechas JD. Management of Fibromyalgia: Rationale for the Use of Magnesium and Malic Acid. J Nutr Med. 1992;3:49-59.
14. Russell IJ, Michalek JE, Fletchas JK, Abraham GE. Treatment of Fibromyalgia Syndrome with Super Malic®: A Randomized, Double Blind, Placebo Controlled, Crossover Pilot Study. J Rheumatol. 1995;22(5):953-958.
15. Durlach J. Recommended Dietary Amounts of Magnesium: Mg RDA. Magnes Res. September 1989;2(3):195-203.
16. National Research Council Subcommittee on the Tenth Edition of the RDAs. Recommended Dietary Allowances. 10th ed. Washington, DC: National Academy Press; 1989:187-194.
17. Abraham GE, Grewal H. A Total Dietary Program Emphasizing Magnesium Instead of Calcium. Effect on the Mineral Density of Calcaneous Bone in Postmeno-pausal Women on Hormonal Therapy. J Reprod Med. May 1990;35(5):503-507.
18. Seelig MS. Magnesium Requirements in Human Nutrition. Magnes Bull. 1981;Ia:26.
19. Dreosti IE. Trace Elements in Nutrition. Med J Aust. August 9 1980;2:117-123.
20. Fox MRS. Effects of Dietary Mineral Levels on Metabolism and Requirements. Neurotoxicology. 1983;4(3):113-120.
21. Marier JR. Comments on Magnesium Intake and Fluoride Intake in the Modern-Day World. Proc Finn Dent Soc. 1980;76:82-92.
22. Burt BA. The Changing Patterns of Systemic Fluoride Intake. J Dent Res. May 1992;71(5):1228-1237
23. Cassidy JT. Progress in Diagnosing and Understanding Chronic Pain Syndromes in Children. Curr Opin Rheumatol. 1994:6(5):544-546.
24. Vercoulen JH, Swanink CM, Fennis JF, et al. Prognosis in Chronic Fatigue Syndrome: A Prospective Study on the Natural Course. J Neurol Neurosurg Psychiatry. May 1996;60(5):489-494.
25. Norregaard J, Bulow PM, Prescott E, et al. A Four-Year Follow-Up Study in Fibromyalgia. Relationship to Chronic Fatigue Syndrome. Scand J Rheumatol. 1993;22(1):35-38.
26. White KP, Speechly M, Harth M, et al. Fibromyalgia in Rheumatology Pra-tice: A Survey of Canadian Rheumatologists. J Rheumatol. April 1995;22(4): 722-726.
27. Ramsay AM. Myalgic Encephalomyelitis and Postviral Fatigue States: The Saga of Royal Free Disease. 2nd Ed. London: Gower Medical Publishing; 1988.
28. Johnson H. Osler's Web: Inside the Labyrinth of the Chronic Fatigue Syndrome Epidemic. New York: Penguin Books; 1996;196-216.
29. Briggs NC, Levine PH. A Comparative Review of Systemic and Neurological Symptomatology in 12 Outbreaks Collectively Described as Chronic Fatigue Syndrome, Epidemic Neuromyasthenia, and Myalgic Encephalomyelitis. Clin Infect Dis. 1994;18(suppl 1):S32-S42.
30. Hyams KC, Wignall FS, Roswell R. War Syndromes and Their Evaluation: From the U. S. Civil War to the Persian Gulf War. Ann Intern Med, September 1 1996;125(5):398-405.
31. Clauw DJ, Chrousos GP. Chronic Pain and Fatigue Syndromes: Overlapping Clinical and Neuroendocrine Features and Potential Pathogenic Mechanisms. Neuroimmunomodulation. May 1997;4(3):134-153.
32. Buchwald D. Fibromyalgia and Chronic Fatigue Syndrome: Similarities and Differences. Rheum Dis Clin North Am. May 1996;22(2):219-243.
33. Bell DS, Bell KM, Cheney PR. Primary Juvenile Fibromyalgia Syndrome and Chronic Fatigue Syndrome in Adolescents. Clin Infect Dis. January 1994;18(suppl 1): S21-S23.
34. Levine PH. Epidemic Neuromyasthenia and Chronic Fatigue Syndrome: Epidemiological Importance of a Cluster Definition. Clin Infect Dis. 1994;18(suppl 1): S16-S20.
35. Bell DS. The Doctor's Guide to Chronic Fatigue Syndrome: Understanding. Treating, and Living with CFIDS. New York: Addison-Wesley; 1995;201-202.
36. Wallach S. Availability of Body Magnesium During Magnesium Deficiency. Magnesium. 1988;7(5-6):262-270.
37. Aikawa JK. The Role of Magnesium in Cellular Processes. In: Magnesium: Its Biologic Significance. Florida: CRC Press; 1981:21-29.
38. Aikawa JK. A General Hypothesis Concerning the Biochemical and Cellular Functions of Magnesium. In: The Relationship of Magnesium to Disease in Domestic Animals and in Humans. Springfield, IL: Charles C. Thomas; 1971;3-43.
39. Whitford GM. The Physiological and Toxicological Characteristics of Fluoride. J Dent Res. February 1990;69:539-549.
40. Kusniec F, Fisher G, Sela BA, et al. Magnesium Protects Against Anaphylactic Shock and Cardiac Myolysis in Guinea-Pigs. J Basic Clin Physiol Pharmacol. Jan 1994;5(1):45-58.
41. Seelig MS. Consequences of Magnesium Deficiency on the Enhancement of Stress Reactions: Preventive and Therapeutic Implications (a review). J Am Coll Nutr. October 1994;13(5):429-446.
42. Aikawa JK. Magnesium Deficiency in Man. In: Magnesium: Its Biologic Significance. Florida: CRC Press: 1981;57-68.
43. Al Ghamdi SM, Cameron EC, Sutton RA. Magnesium Deficiency: Pathophysiologic and Clinical Overview. Am J Kidney Dis. November 1994;24(5):737-752.
44. Langley WF, Mann D, Central Nervous System Magnesium Deficiency. Arch Intern Med. March 1991;151(3):593-596.
45. Morris ME. Brain and CSF Magnesium Concentrations During Magnesium Deficit in Animals and Humans: Neurological Symptoms. Magnes Res. December 1992;5(4):303-313.
46. Zaloga GP, Chernow B, Pock A, et al. Hypomagnesemia is a Common Complication of Aminoglycoside Therapy. Surg Gynecol Obstet. June 1984;158(6): 561-565.
47. Kaloyanides GJ. Antibiotic-Related Nephrotoxicity. Nephrol Dial Transplant. 1994;9(suppl 4):130-134.
48. Rylander R. Environmental Magnesium Deficiency as a Cardiovascular Risk Factor. J Cardiovasc Risk. February 1996:3(1):4-10.
49. Marier JR. Magnesium Content of the Food Supply in the Modern-Day World. Magnesium. 1986;5(1):1-8.
50. Durlach J, Durlach V, Bac P, et al. Magnesium and Ageing. II. Clinical Data: Aetiological Mechanisms and Pathophysiological Consequences of Magnesium Deficit in the Elderly. Magnes Res. December 1993;6(4):379-394.
51. Seelig MS, Auto-Immune Complications of D-Penicillamine-A Possible Result of Zinc and Magnesium Depletion and of Pyridoxine Inactivation. J Am Coll Nutr: 1982;1:207-214.
52. Rivlin RS. Magnesium Deficiency and Alcohol Intake: Mechanisms, Clinical Significance and Possible Relation to Cancer Development (a review). J Am Coll Nutr. 1994;13(5):416-423.
53. Manocha SL, Warner H, Olkowski ZL. Cytochemical Response of Kidney, Liver and Nervous System to Fluoride Ions in Drinking Water. Histochem J. 1975;7:343-355.
54. Mclvor ME. Acute Fluoride Toxicity: Pathophysiology and Management. Drug Saf. 1990;5(2):79-85.
55. Spittle B. Psychopharmacology of Fluoride: A Review, Int Clin Psychopharmacol. 1994;9:79-82.
56. Grandjean P. Classical Syndromes in Occupational Medicine. Occupational Fluorosis Through 50 Years: Clinical and Epidemiological Experiences. Am J Ind Med. 1982;3:227-236.
57. Roholm K. Fluorine Intoxication. A Clinical-Hygienic Study with a Review of the Literature and Some Experimental Investigations. London: H. K. Lewis &. Co., Ltd.; 1937.
58. Shupe JL, Peterson HB, Leone NC, eds. Fluorides: Effects on Vegetation, Animals and Humans. Salt Lake City, UT: Paragon Press; 1983.
59. Arnbjornsson E. Arnhjornsson A, Olafsson A. Thyroid Cancer Incidence in Relation to Volcanic Activity. Arch Environ Health. January 1986;41(1):36-40.
60. Guan Z-Z, Zhuang Z, Yang P-S, et al. Synergistic Action of Iodine-Deficiency and Fluorine-Intoxication on Rat Thyroid. Chin Med J. 1988;10(9):679-684.
61. Kishi K, Ishida T. Clastogenic Activity of Sodium Fluoride in Great Ape Cells. Mutat Res. 1993;301:183-188.
62. Kharasch ED. Metabolism and Toxicity of the New Anesthetic Agents. Acta Anaesthesiol Belg. 1996;47(1):7-14.
63. Lochhead KM, Kharasch ED, Zager RA. Spectrum and Subcellular Determinants of Fluorinated Anesthetic-Mediated Proximal Tubular Injury. Am J Pathol. June 1997;150(6):2209-2221.
64. Martin JL, Plevak DJ, Flannery KD, et al. Hepatotoxicity After Desflurane Anesthesia. Anesthesiology. 1995;83:1125-1129.
65. National Research Council Committee on Toxicology. Health Effects of Ingested Fluoride. Washington: National Academy Press; 1993.
66. Whitford GM, Pashley DH. Fluoride Absorption: The Influence of Gastric Acidity. Calcif Tissue Int. 1984;36:302-307.
67. Whitford GM. The Metabolism and Toxicity of Fluoride. In: Myers HM ed. Monographs In Oral Science. Vol 13. Basel: Karger: 1989.
68. Spak CJ, Berg U, Ekstrand J. Renal Clearance of Fluoride in Children and Adolescents. Pediatrics. 1985;75(3):575-579.
69. Lantz O, Jouvin MH, de Vernejoul MC, et al. Fluoride-Induced Chronic Renal Failure. Am J Kidney Dis, 1987;10(2):136-139.
70. Bond AM, Murray MM. Kidney Function and Structure in Chronic Fluorosis. Br J Exp Pathol. 1952;33(2):168-176
71. National Research Council Committee on Animal Nutrition. Mineral Tolerance of Domestic Animals. Washington, DC: National Academy Press: 1980:189.
72. Taves DR. Is Fluoride Intake in the United States Changing? In: Johansen E, Taves DR, Olsen TO, eds. Continuing Evaluation of the Use of Fluorides. Boulder, CO: Westview Press; 1979:149-151.
73. Chen Y, Lin M, He Z, et al. Air Pollution-Type Fluorosis in the Region of Pingxiang, Jiangxi, Peoples' Republic of China. Arch Environ Health. July/August 1993;48(4):246-249.
74. Krishnamachari KAVR. Skeletal Fluorosis in Humans: A Review of Recent Progress in the Understanding of the Disease. Prog Food Nutr Sci. 1986;10:279-314.
75. Susheela AK, Jethanandani P. Serum Haptoglobin and C-Reactive Protein in Human Skeletal Fluorosis. Clin Biochem. 1994;27(6):463-468.
76. Anand JK, Roberts JT. Chronic Fluoride Poisoning in Man: A Review of Literature in English (1946-1989) and Indications for Research. Biomed Pharmacother. 1990;44:417-420.
77. Susheela AK, Kharb P. Aortic Calcification in Chronic Fluoride Poisoning: Biochemical and Electronmicroscopic Evidence. Exp Mol Pathol. 1990;53:72-80.
78. Weiner SR. Growing Pains. Am Fam Physician. January 1983;27(1):189-191.
79. Kleerekoper M. Fluoride and the Skeleton. Crit Rev Clin Lab Sci. 1996; 33(2):139-161.
80. Kleerekoper M. Fluoride and the Skeleton. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. New York: Academic Press; 1996:1053-1062.
81. Grandjean P, Thomsen G. Reversibility of Skeletal Fluorosis. Br J Ind Med, 1983;40:456-461.
82. Talbot JR, Fischer MM, Farley SM, et al. Gains Made in Spinal Bone Density in Response to Fluoride Therapy for Osteoporosis Arc Not Maintained After Fluoride Therapy is Discontinued. J Bone Miner Res. 1991;7(suppl 1):118 (abstract).
83. Karczmar AG. Brief Presentation of the Story and Present Status of Studies of the Vertebrate Cholinergic System. Neuropsychopharmacology. 1993;9(3):181-199.
84. Bennett RM, Cook DM, Clark SR, et al. Hypothalamic-Pituitary-Insulin-Like Growth Factor-1 Axis Dysfunction in Patients with Fibromyalgia. J Rheumatol. July 1997;24(7):1384-1389.
85. Demitrack MA. Neuroendocrine Correlates of Chronic Fatigue Syndrome: A Brief Review. J Psychiatr Res. 1997;31(1):69-82.
86. Standaert FG. Pharmacology of the Neuromuscular Junction. In: Brumback RA, Gerst JW, eds. The Neuromuscular Junction. Mount Kisco, NY: Futura Publishing Co.; 1984:121-294.
87. Callister RJ, Sah P. The Removal of Acetylcholine by Diffusion at Nicotinic Synapses in the Rat Otic Ganglion. J Physiol. 1997;505(1):165-175.
88. Crofford LJ, Demitrack MA. Evidence That Abnormalities of Central Neurohormonal Systems Are Key to Understanding Fibromyalgia and Chronic Fatigue Syndrome. Rheum Dis Clin North Am. May 1996;22(2):267-284.
89. Dryden WF, Singh YN, Gordon T, et al. Pharmacological Elevation of Cyclic AMP and Transmitter Release at the Mouse Neuromuscular Junction. Can J Physiol Pharmacol. March 1988;66(3):207-212.
90. Silver A. Some Enzymological Aspects of Acetylcholinesterase. In: The Biology of Cholinesterases. Amsterdam: North Holland Publishing Co.; 1974:10. Neuberger A, Tatum EL. eds. Frontiers of Biology; vol. 36.
91. Taylor P. Anticholinesterase Agents. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:161.
92. Hattori T, Maehashi H. Excitation of Skeletal Muscle by Fluoride. In: Tsunoda H, Yu M-H eds. Fluoride Research 1985. Amsterdam: Elsevier; 1986:277-284. Studies in Environmental Science: vol. 27.
93. Beauregard CL, Smith PG. Parasympathetic Excitation of Sympathetic Innervation After Cholinesterase Inhibition. Br J Pharmacol. 1996; 117:51-54.
94. Martin AE. Fluorides and General Health: Introduction. In: Fluorides and Human Health. Geneva: World Health Organization; 1970:273.
95. Selwitz RH. Strategies for Improving Methods of Assessing Fluoride Accumulation in Body Fluids and Tissues. Adv Dent Res. June 1994;8(1):111-112.
96. National Research Council Committee on Biologic Effects of Atmospheric Pollutants. Fluorides. Washington, DC: National Academy of Sciences; 1971:4.
97. Shimonovitz S, Patz D, Ever-Hadani P, et al. Umbilical Cord Fluoride Serum Levels May Not Reflect Fetal Fluoride Status. J Perinat Med. 1995;23(4):279-282.
98. Bramhilla E, Belluomo G, Malerba A, et al. Oral Administration of Fluoride in Pregnant Women, and the Relation Between Concentration in Maternal Plasma and in Amniotic Fluid. Arch Oral Biol. November 1994;39(11):991-994.